ArticleMolecular genetics and metabolism reports2025
Family hypercholesterolemia due to
Article in Molecular genetics and metabolism reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Compound heterozygous familial hypercholesterolemia in a pediatric patient with multiple cutaneous xanthomas.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Familial hypercholesterolemia (FH) results in elevated LDL cholesterol, contributing to atherosclerosis and early-onset cardiovascular disease. Mutations in the low-density lipoprotein receptor gene are the most common cause of familial hypercholesterolemia. Information regarding hypercholesterolemia in low- and middle-income nations is inadequate. This research aimed to characterise the phenotype and genotype of Vietnamese children diagnosed with familial hypercholesterolemia. Methods: This study included twenty-one children diagnosed with familial hypercholesterolemia from 15 unrelated families. Data regarding physical characteristics, biochemical testing, cardiac ultrasound, coronary angiography, and dual-source computed tomography were gathered at diagnosis and follow-up. Next-generation and Sanger sequencing were performed to identify disease-causing variants in twenty-one index cases. Results: We found eighteen heterozygous and two homozygous/one compound heterozygous FH cases. Fourteen distinct variants were identified, with the most prevalent being c.664 T > C and c.681C>G, and exon 15 deletion. Furthermore, we identified the c.161A>C variant, which remains unreported in the literature. The median age at diagnosis was 6.7 years (0.5-17.5) and 8.3 years (6.3-13.3) in heterozygous and homozygous/compound heterozygous groups, respectively. 100 % homozygous/compound heterozygous cases and 16.7 % heterozygous cases presented xanthomas. The median plasma levels of LDL in heterozygous and homozygous/compound heterozygous groups were 6.6 mmol/l (3.8-12) and 10.8 mmol/l (10.7-11.7), respectively. Conclusions: FH can appear early in childhood, and xanthomas primarily manifest in homozygous FH patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.